Plasmodium falciparum merozoite surface protein 3 and glutamate-rich protein (MSP3/GLURP)

The target consists of two key antigens from the asexual blood stage of the malaria parasite Plasmodium falciparum: Merozoite Surface Protein 3 (MSP3) and Glutamate-Rich Protein (GLURP) [4, 7]. MSP3 is a soluble protein associated with the merozoite surface through protein-protein interactions, while GLURP is expressed across multiple stages of the parasite's life cycle in the human host [13, 26]. Both proteins are critical targets of the naturally acquired immune response in individuals living in malaria-endemic regions [1, 15]. High titers of specific cytophilic antibodies (IgG1 and IgG3) against these antigens are strongly associated with protection from clinical malaria [3, 6]. The primary therapeutic strategy targeting these molecules is the development of vaccines, most notably the GMZ2 fusion protein, which combines conserved domains of both GLURP and MSP3 [9, 14]. The mechanism of action for these vaccines involves the induction of antibodies that cooperate with host monocytes to inhibit parasite growth through antibody-dependent cellular inhibition (ADCI) [2, 13]. While clinical trials have demonstrated that these targets are safe and immunogenic, the efficacy of current formulations like GMZ2 has been modest in Phase IIb trials [7, 12]. Ongoing research focuses on improving vaccine potency through the use of novel adjuvants and multi-stage antigen combinations [4, 5].

Other names

MSP3GLURPGMZ2Secreted polymorphic antigen associated with merozoitesSPAMPF3D7_1035400PF3D7_1035300

Induction of cytophilic antibodies (IgG1 and IgG3) that mediate antibody-dependent cellular inhibition (ADCI) of parasite growth in cooperation with monocytes.